Tagged with Opinion,

USA Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs” in the US and the steps that need to be taken to remedy the situation.   Globally, 700,000 people lose their lives to drug-resistant infections each year In November 2019,…

Opinion Monica Weldon, CEO and president of Bridge the Gap – SYNGAP Education and Research Foundation, shares her recent experience at the US Drug Law and Regulation course in Washington, DC and expands on the role that patient associations can play in the drug development process.   In today’s environment of…

Opinion Michael Jewell, partner and head of healthcare & life sciences at Cavendish Corporate Finance looks back at the key trends across pharma industry funding in 2019 and gives his perspective on how 2020 will look.   As we approach the end of 2019, it’s a good time to look back…

Opinion Steve Brooks, Advisor to the AMR Industry Alliance, outlines the threat that antimicrobial resistance (AMR) poses to global health,  how antibiotic manufacturing may be a contributing factor to AMR  and how responsible manufacturing processes can minimize any such contribution.   The causes of antimicrobial resistance are numerous, from over prescribing to…

Global The IFPMA’s Greg Perry shares some of the key findings from a panel discussion on access to healthcare products at the 2019 World Health Summit in Berlin and the vital importance of cross-sector partnerships in driving access to medicines and vaccines across the globe.   In October I had the…

Opinion This month, Aditya Bhattacharji takes stock of three political issues that are dominating Eurasia Group’s conversations with pharmaceutical firms: global protests, drug pricing, and India’s “Modicare” milestone.    Protests First, the rash of protests unfolding across parts of the Middle East, Asia, and Latin America has piqued firms’ attention—not just…

Opinion Anthony Harrington of global investment banking and asset management firm Alantra outlines why healthcare and consulting communications companies are increasingly attractive targets for private equity.   The supply of PE money chasing fewer and fewer assets is only going to increase the attraction of healthcare communications and consulting firms to…

USA Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene therapies in the US and beyond.   To keep pace with the remarkable and continuing growth of gene therapy, FDA’s…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

USA AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward.   Discussion and debate related to cost and quality in healthcare has never been more pronounced or more contentious, whether focusing on…

USA Carla Smith looks at the various cybersecurity risks that exist across the US healthcare continuum and the steps that executive leadership can take to combat this threat.   Keeping patient data safe and secure remains a challenge. Thanks to a 9-year review of experiences in the United States, we know…

Opinion Within the pharmaceutical space, Eurasia Group’s Aditya Bhattacharji expects politics to drive significant changes in regulatory and legal affairs. He explains how the evolving dynamics can be characterized by two themes.   Regulatory Right-Sizing The status quo is highly unlikely to hold in the regulatory space. The growing and largely…